Laboratory and clinical studies of sparfloxacin

We performed laboratory and clinical evaluations of sparfloxacin, a new oral quinolone, with the following results. 1 ) Antimicrobial activity The minimum inhibitory concentrations (MIC_s) of sparfloxacin for a total of 309 clinically isolated strains were determined and compared with those of tosufloxacin, ofloxacin, and ciprofloxacin, using the MIC-2000 system. Sparfloxacin had wide antimicrobial activities to clinically isolated strains except methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Especially, sparfloxacin showed better MIC_sto Streptococcus pneumoniae than the compared antimicrobial agents. 2 ) Clinical efficacy Sparfloxacin (300 mg/day) was administered to 1 patient with bacterial pneumonia and 1 patient with chronic bronchitis two times per day. Four patients with chronic bronchitis were treated with sparfloxacin (300 mg) in once a day medication. Clinical responses were excellent in 1 patient, and good in 5 patients. Clinical efficacy rate was 100%. One strain of Haemophilus influenzae was isolated and eradicated. Side effects, and abnormally altered laboratory findings were not observed in all patients.